Cargando…

Aspirin has little additional anti-platelet effect in healthy volunteers receiving prasugrel

SUMMARY: Background: Strong P2Y(12) blockade, as can be achieved with novel anti-platelet agents such as prasugrel, has been shown in vitro to inhibit both ADP and thromboxane A(2)-mediated pathways of platelet aggregation, calling into question the need for the concomitant use of aspirin. Objective...

Descripción completa

Detalles Bibliográficos
Autores principales:	LEADBEATER, P D M, KIRKBY, N S, THOMAS, S, DHANJI, A-R, TUCKER, A T, MILNE, G L, MITCHELL, J A, WARNER, T D
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3338354/ https://www.ncbi.nlm.nih.gov/pubmed/21794076 http://dx.doi.org/10.1111/j.1538-7836.2011.04450.x

Ejemplares similares

Antiplatelet effects of aspirin vary with level of P2Y(12) receptor blockade supplied by either ticagrelor or prasugrel
por: KIRKBY, N S, et al.
Publicado: (2011)

Platelet Aggregation Inhibitory Effects and Pharmacokinetics of Prasugrel Used in Combination With Aspirin in Healthy Japanese Subjects
por: Umemura, Kazuo, et al.
Publicado: (2016)

Aspirin inhibits the production of proangiogenic 15(S)-HETE by platelet cyclooxygenase-1
por: Rauzi, Francesca, et al.
Publicado: (2016)

Pharmacokinetic Interaction Between Prasugrel and Ritonavir in Healthy Volunteers
por: Ancrenaz, Virginie, et al.
Publicado: (2013)

The Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Japanese Volunteers
por: Umemura, Kazuo, et al.
Publicado: (2016)

Stability-indicating HPLC Method for Simultaneous Determination of Aspirin and Prasugrel
por: Patel, Shital M., et al.
Publicado: (2013)

Bleeding Complication of Triple Therapy of Rivaroxaban, Prasugrel, and Aspirin: A Case Report and General Discussion
por: Gruenebaum, Dane D., et al.
Publicado: (2014)

Morphine interaction with prasugrel: a double-blind, cross-over trial in healthy volunteers
por: Hobl, Eva-Luise, et al.
Publicado: (2015)

Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor
por: Adamski, Piotr, et al.
Publicado: (2022)

No Pharmacokinetic Drug–Drug Interaction Between Prasugrel and Vorapaxar Following Multiple‐Dose Administration in Healthy Volunteers
por: Anderson, Matt S., et al.
Publicado: (2017)

Comparison of Three Aspirin Formulations in Human Volunteers
por: Nordt, Sean Patrick, et al.
Publicado: (2011)

Eicosanoids in platelets and the effect of their modulation by aspirin in the cardiovascular system (and beyond)
por: Crescente, Marilena, et al.
Publicado: (2018)

Review of Prasugrel for the Secondary Prevention of Atherothrombosis
por: Spinler, Sarah A., et al.
Publicado: (2009)

Diabetes mellitus and platelet reactivity in patients under prasugrel or ticagrelor treatment: an observational study
por: Alexopoulos, Dimitrios, et al.
Publicado: (2015)

Influence of body size on platelet response to ticagrelor and prasugrel in patients with acute coronary syndromes
por: Ndrepepa, Gjin, et al.
Publicado: (2021)

Differential Effects of Ticagrelor With or Without Aspirin on Platelet Reactivity and Coagulation Activation: A Randomized Trial in Healthy Volunteers
por: Traby, Ludwig, et al.
Publicado: (2019)

Researches on a Disease Yet but Little Known, Which Has Received the Name of Softening of the Brain
Publicado: (1820)

Prasugrel in critically ill patients
por: Schoergenhofer, Christian, et al.
Publicado: (2017)

Interactions of fentanyl with blood platelets and plasma proteins: platelet sensitivity to prasugrel metabolite is not affected by fentanyl under in vitro conditions
por: Bednarek, Radosław, et al.
Publicado: (2023)

Impact of Prasugrel and Ticagrelor on Platelet Reactivity in Patients With Acute Coronary Syndrome: A Meta-Analysis
por: Dai, Lulu, et al.
Publicado: (2022)

Association between Platelet Count and Treatment Effect of Ticagrelor or Prasugrel in Patients with Acute Coronary Syndromes
por: Koch, Tobias, et al.
Publicado: (2023)

Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy?
por: Langley, R E, et al.
Publicado: (2011)

TRITON and Beyond: New Insights into the Profile of Prasugrel
por: Jakubowski, Joseph A, et al.
Publicado: (2012)

Reduction of thromboembolic complications during the endovascular treatment of unruptured aneurysms by employing a tailored dual antiplatelet regimen using aspirin and prasugrel
por: Higashiguchi, Saeko, et al.
Publicado: (2021)

Prasugrel-Induced Hypersensitivity Skin Reaction
por: Kim, Soo-Han, et al.
Publicado: (2014)

Prasugrel for Secondary Prevention of Thrombotic Stroke
por: Yagita, Yoshiki
Publicado: (2023)

Comparison of platelet reactivity between prasugrel and ticagrelor in patients with acute coronary syndrome: a meta-analysis
por: Wen, Mingxiang, et al.
Publicado: (2020)

Platelets, Aspirin and Cardiovascular Disease
por: Elwood, P. C.
Publicado: (1976)

Fifty years with aspirin and platelets
por: Patrono, Carlo
Publicado: (2022)

Audit of Resucitation Decisions Has Little Impact on Clinical Practice
por: Hayes, S, et al.
Publicado: (1999)

Comparison of lower loading dose of prasugrel with conventional loading dose of prasugrel in Indian patients undergoing percutaneous coronary interventions
por: Kumari, Priti, et al.
Publicado: (2018)

Anti-platelet effects of epigallocatechin-3-gallate in addition to the concomitant aspirin, clopidogrel or ticagrelor treatment
por: Joo, Hyung Joon, et al.
Publicado: (2018)

Derivation of a Novel Scoring System Predicting High Platelet Reactivity on Prasugrel in Patients with Coronary Artery Disease
por: Saito, Yuichi, et al.
Publicado: (2022)

Aspirin, clopidogrel and prasugrel monotherapy in patients with type 2 diabetes mellitus: a double-blind randomised controlled trial of the effects on thrombotic markers and microRNA levels
por: Parker, William A. E., et al.
Publicado: (2020)

Influence of Sex on Platelet Reactivity in Response to Aspirin
por: Friede, Kevin A., et al.
Publicado: (2020)

Aspirin blocks formation of metastatic intravascular niches by inhibiting platelet-derived COX-1/thromboxane A(2)
por: Lucotti, Serena, et al.
Publicado: (2019)

Prasugrel for the treatment of patients with acute coronary syndrome
por: Marzot, Filippo, et al.
Publicado: (2009)

Eversion endarterectomy under full prasugrel treatment
por: Kotsis, Thomas, et al.
Publicado: (2017)

Low-Dose Prasugrel in Treatment of Cerebral Aneurysms
por: Kang, Hyun-Seung
Publicado: (2018)

Critical Review of Prasugrel for Formulary Decision Makers
por: Schafer, Jeremy
Publicado: (2009)

Cannot write session to /tmp/vufind_sessions/sess_m2jmbk3nss3qoa25lj6la0h7nq